Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure

European Journal of Heart Failure

Volumn 10, Issue 2, 2008, Pages 125-128

  Yan, Andrew T ^{a,b,c,d,e,f,g}   Yan, Raymond T ^{a,b,c,d,e,f,g}   Spinale, Francis G ^{a,b,c,d,e,f,g}   Afzal, Rizwan ^{a,b,c,d,e,f,g}   Gunasinghe, Himali R ^{a,b,c,d,e,f,g}   Stroud, Robert E ^{a,b,c,d,e,f,g}   McKelvie, Robert S ^{a,b,c,d,e,f,g}   Liu, Peter P ^{a,b,c,d,e,f,g}  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart failure; Matrix metalloproteinase; Neurohormones

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; NORADRENALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME BLOOD LEVEL; FEMALE; HEART FAILURE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINOLOGY; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

AGED; ALDOSTERONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOTHELIN-1; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEUROTRANSMITTER AGENTS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 39149095924     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.12.002     Document Type: Article

References (23)

1. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
2. Yan A.T., Yan R.T., and Liu P.P. Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med 142 (2005) 132-145
3. Spinale F.G. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
4. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
5. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
6. Peterson J.T., Hallak H., Johnson L., et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 (2001) 2303-2309
7. Coker M.L., Jolly J.R., Joffs C., et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 281 (2001) H543-H551
8. Tsuruda T., Boerrigter G., Huntley B.K., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
9. Banfi C., Cavalca V., Veglia F., et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26 (2005) 481-488
10. Deschamps A.M., and Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 69 (2006) 666-676
11. Tsuyuki R.T., Yusuf S., Rouleau J.L., et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Can J Cardiol 13 (1997) 1166-1174
12. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure - Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 100 (1999) 1056-1064
13. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy - the Randomized Evaluation of Strategies for Left Ventricular Dysfunction pilot study. Circulation 101 (2000) 378-384
14. Wilson E.M., Gunasinghe H.R., Coker M.L., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8 (2002) 390-398
15. Yan A.T., Yan R.T., Spinale F.G., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12 (2006) 514-519
16. Ohtsuka T., Hamada M., Saeki H., et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 91 (2003) 1024-1027
17. Squire I.B., Evans J., Ng L.L., Loftus I.M., and Thompson M.M. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10 (2004) 328-333
18. Yamazaki T., Lee J.D., Shimizu H., Uzui H., and Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6 (2004) 41-45
19. Tziakas D.N., Chalikias G.K., Hatzinikolaou E.I., et al. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96 (2005) 31-34
20. George J., Patal S., Wexler D., Roth A., Sheps D., and Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150 (2005) 484-487
21. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
22. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
23. Suzuki G., Morita H., Mishima T., et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 (2002) 2967-2972